ChromaTan Wins $2.5M FDA Contract to Develop Integrated Continuous Purification Platform

ChromaTan has won a $2.5 million FDA contract toward process development, design, and testing of an integrated, continuous downstream purification platform for production of monoclonal antibodies
Hand holding crystal ball

The Transparent CDMO: Maintaining Autonomy in Your Biomanufacturing Partnership

Sponsored Content Brought to you by Collaboration with a contract development and manufacturing organization (CDMO) can make it possible to bring your drug to market — and to patients — faster, as additional resources allow...
Intertek Pharmaceutical Services laboratory techniques

Antibody Characterization Keeps Pace with the Antibody Industry

Biologic monoclonal antibody (mAb) drugs are not just more targeted than small-molecule drugs, they are also larger, more complicated, and more variable. Consequently, biologic mAb drugs, which generate sizable revenues, may enjoy some degree...

Passage Bio Partnering with Catalent’s Paragon to Manufacture Gene Therapies

Passage Bio, a developer of gene therapies for rare monogenic CNS diseases launched five months ago, will partner with Catalent’s Paragon Gene Therapy unit to develop a dedicated manufacturing suite at Paragon’s Harmans, MD, facility.
Lab research

Case Study: Accelerate the Time from DNA to Material

In this MilliporeSigma sponsored content, we explores they'r mini-pool approach as fast track process for small biotechs who are on a very challenging timeline. It enables us to start process development and production of early material before cell line development is completed.

Transgene and Vivalis to Evaluate MVA Vaccine Production in EB66 Duck Stem Cell Line

Firm is looking for alternative platform to CEF manufacture for clinical-stage cancer and infectious disease vaccines.

MilliporeSigma Inks Vaccine Manufacturing Deal with South Korean Institute

MilliporeSigma signed a research agreement with the International Vaccine Institute (IVI) to help develop more scalable vaccine manufacturing processes

Quanterix Set to Launch IPO, with Expansion and SR-X Rollout in Mind

Quanterix plans to launch an IPO of at least $64 million, with proceeds set in part toward expanding commercial operations and supporting the planned rollout next year of its new Quanterix SR-X Ultra-Sensitive Biomarker Detection System™
filtration workflow

Filtration Focuses on Capacity and Concentration Pain Points

A therapeutic protein or monoclonal antibody (mAb) can be turned into an effective therapy and a revenue-generating product only if it can be efficiently filtered from the process stream. If a product is inefficiently...

Single-Use Technology: Enjoy the Upsides, Handle the Downsides

When new technologies are deployed, there’s always a fly in the ointment. In the case of single-use technology, extractables and leachables must be swatted away.

Recently Featured

Stay Connected

Scroll Up